The present study confirms and extends these data revealing that aCL/Vim antibodies are present in 54% of OSN-APS patients, with a prevalence significantly higher as compared to aPS/PT (12%) in this specific group of SN-APS patients. This evidence concerns the gene ACLY and autoimmune polyendocrinopathy.